WHO Pharmaceuticals Newsletter 1999, No. 07&08
(1999; 18 pages)
Índice de contenido
Cerrar esta carpetaRegulatory actions
Ver el documentoAlbumin (human): review of safety: conclusions: UK
Ver el documentoAstemizole: voluntary withdrawal: Janssen, USA
Ver el documentoCisapride: revised labelling: QT syndrome and drug interactions: USA
Ver el documentoFollitropin alfa: batch withdrawn: stability problems: EU
Ver el documentoHetastarch (hydroxyethylstarch): fatal haemorrhages: France
Ver el documentoMinocycline: immunoallergic and liver damage with long-term therapy: Germany
Ver el documentoOral contraceptives containing gestodene or desogestrel: update: revised product information: UK
Ver el documentoPemoline: revised labelling: liver function monitoring: Abbott, USA
Ver el documentoPhenol: warning concerning topical solutions: New Zealand
Ver el documentoProgestational drug products: requirements for patient labelling: proposed rule: USA
Ver el documentoSubstandard medicines: distribution and prescription prohibited: Venezuela
Ver el documentoSunscreen products: requirements: final rule: USA
Ver el documentoTranylcypromine/trifluoperazine: licence not renewed: UK
Ver el documentoTroglitazone: restricted indications: USA
Ver el documentoTrovafloxacin and alatrofloxacin: suspended: Spain
Abrir esta carpeta y ver su contenidoDrug surveillance
Abrir esta carpeta y ver su contenidoNew developments
Abrir esta carpeta y ver su contenidoMedical devices
Abrir esta carpeta y ver su contenidoMedication errors
Abrir esta carpeta y ver su contenidoGeneral information
 

Follitropin alfa: batch withdrawn: stability problems: EU

European Union. The European Agency for the Evaluation of Medicinal Products has issued a Defective Product Recall concerning one batch of follitropin alfa (Gonal-F 150 IU: Serono Pharma) after quality control tests revealed concerns about stability.

The batch: No. B-3425: was found to be out of specification for Oxidized Forms at 3 months check points of the Stability Studies (19% vs 10% limit at shelf life). All other parameters were found to be within the limits.

The batch was distributed to Denmark, Finland, France, Germany, Italy, Sweden, UK and Latin America. It has been withdrawn by the company.

Reference: Defective Product Recall: EMEA, 5 May 1999.

Ir a la sección anterior Ir a la siguiente sección
 

Última actualización: le 3 mayo 2013